You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 13, 2024

Litigation Details for In Re: National Prescription Opiate Litigation (N.D. Ohio 2022)

✉ Email this page to a colleague

« Back to Dashboard

In Re: National Prescription Opiate Litigation (N.D. Ohio 2022)

Docket	⤷ Sign Up	Date Filed	2022-11-04
Court	District Court, N.D. Ohio	Date Terminated
Cause	28:1446 Petition for Removal- Personal Injury	Assigned To	Dan A. Polster
Jury Demand	Both	Referred To
Parties	PEMBROKE PHARMACY, INC.; STEVEN A HOLPER, M.D., PROFESSIONAL CORPORATION
Patents	10,124,000; 4,850,305; 6,106,864; 6,200,604; 6,417,175; 6,488,963; 6,545,040; 6,602,911; 6,649,180; 6,667,050; 6,893,662; 6,906,055; 6,913,768; 6,958,326; 6,992,218; 7,030,149; 7,163,931; 7,192,938; 7,304,036; 7,320,969; 7,320,976; 7,371,727; 7,410,957; 7,419,973; 7,642,258; 7,645,459; 7,645,460; 7,668,730; 7,704,947; 7,704,984; 7,718,634; 7,741,358; 7,745,409; 7,765,106; 7,765,107; 7,790,199; 7,803,838; 7,829,121; 7,834,020; 7,838,552; 7,851,482; 7,888,342; 7,895,059; 7,947,739; 7,994,220; 8,008,338; 8,022,082; 8,022,106; 8,022,228; 8,038,988; 8,039,009; 8,058,291; 8,080,526; 8,101,593; 8,110,553; 8,133,890; 8,168,209; 8,173,708; 8,193,195; 8,207,215; 8,217,083; 8,236,804; 8,242,294; 8,246,989; 8,263,054; 8,273,795; 8,283,379; 8,293,794; 8,309,060; 8,309,122; 8,329,216; 8,329,752; 8,338,485; 8,338,486; 8,344,011; 8,354,409; 8,362,085; 8,367,649; 8,377,982; 8,436,051; 8,457,988; 8,461,140; 8,481,598; 8,486,972; 8,486,973; 8,541,466; 8,546,367; 8,580,858; 8,589,182; 8,598,233; 8,629,111; 8,632,760; 8,633,162; 8,642,556; 8,648,048; 8,653,058; 8,664,215; 8,673,921; 8,685,930; 8,731,963; 8,748,425; 8,748,573; 8,758,733; 8,772,306; 8,802,628; 8,808,737; 8,808,741; 8,846,100; 8,865,937; 8,871,779; 8,883,770; 8,894,987; 8,894,988; 8,906,950; 8,906,962; 8,926,953; 8,933,030; 8,946,281; 8,986,715; 9,010,323; 9,050,302; 9,060,976; 9,073,933; 9,173,857; 9,175,017; 9,216,183; 9,226,931; 9,248,191; 9,302,009; 9,399,012; 9,399,025; 9,486,426; 9,492,389; 9,492,391; 9,492,392; 9,492,393; 9,517,219; 9,522,155; 9,522,919; 9,579,270; 9,604,009; 9,636,349; 9,708,371; 9,770,453; 9,907,801; 9,907,802; 9,949,986; 9,957,480; RE43,879
Attorneys	Brent M. Buckley; Jim C. McGough
Firms	Brent M. Buckley; Hogan Lovells US Baltimore; Lamp Bartram Levy Trautwein & Perry
Link to Docket	External link to docket

Small Molecule Drugs cited in In Re: National Prescription Opiate Litigation

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .

Biologic Drugs cited in In Re: National Prescription Opiate Litigation

The biologic drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .

Details for In Re: National Prescription Opiate Litigation (N.D. Ohio 2022)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2019-06-21	1717	Exhibit s to Chalos Declaration	infringed U.S. Patent Nos. 6,028,222 ("the '222 patent") and 6,992,218 ("the '…concerning ten patents covering Inomax (i.e., five patents expiring in 2029 and five patents expiring in…in the five patents expiring in 2031 are patentable. '222 and '218 Patent Litigation:… such investigation. Patent/Antitrust Litigation Inomax Patent Litigation: Praxair Distribution…this group of patents and the PTAB ruled in July 2016 that one claim of this patent survived review	External link to document
2019-07-03	1812	Exhibit 16 - Chalos Dec.:MNK 2016 10Q	infringed U.S. Patent Nos. 6,028,222 ("the '222 patent") and 6,992,218 ("the '…concerning ten patents covering Inomax (i.e., five patents expiring in 2029 and five patents expiring in…in the five patents expiring in 2031 are patentable. '222 and '218 Patent Litigation:… such investigation. Patent/Antitrust Litigation Inomax Patent Litigation: Praxair Distribution…this group of patents and the PTAB ruled in July 2016 that one claim of this patent survived review	External link to document
2019-07-09	1823	Exhibits 1-37 [redacted] to the Egler Declaration	Warner Chilcott’s U.S. Patent No. 6,893,662, expiring in November 2021 (the “‘662 Patent”), is invalid and/…) U.S. Patent No. 5,541,170 (the “‘170 Patent”) and U.S. Patent No. 5,541,171 (the “‘171 Patent”), formulation…Chilcott’s U.S. Patent Nos. 7,645,459 (the “‘459 Patent”) and 7,645,460 (the “‘460 Patent”), two formulation…infringement of the ‘459 Patent and ‘460 Patent. On August 21, 2012, the United States Patent and Trademark Office…to the Company U.S. Patent No. 8,246,989 (the “‘989 Patent”), a formulation patent expiring in January	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.